Cargando…

The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure

Background: adropin plays a protective role in cardiac remodeling through supporting energy metabolism and water homeostasis and suppressing inflammation. Low circulating levels of adropin were positively associated with the risk of cardiovascular diseases and type 2 diabetes mellitus (T2DM). We hyp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berezin, Alexander A., Obradovic, Zeljko, Fushtey, Ivan M., Berezina, Tetiana A., Novikov, Evgen V., Schmidbauer, Lukas, Lichtenauer, Michael, Berezin, Alexander E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953100/ https://www.ncbi.nlm.nih.gov/pubmed/36830993 http://dx.doi.org/10.3390/biomedicines11020457

Ejemplares similares

Adropin Predicts Chronic Kidney Disease in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure
por: Berezina, Tetiana A., et al.
Publicado: (2023)

Low Plasma Levels of Irisin Predict Acutely Decompensated Heart Failure in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure
por: Berezin, Alexander A., et al.
Publicado: (2023)

The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure
por: Berezin, Alexander A., et al.
Publicado: (2022)

Interplay between Myokine Profile and Glycemic Control in Type 2 Diabetes Mellitus Patients with Heart Failure
por: Berezin, Alexander A., et al.
Publicado: (2022)

The Association of Glucose Control with Circulating Levels of Red Blood Cell-Derived Vesicles in Type 2 Diabetes Mellitus Patients with Atrial Fibrillation
por: Berezin, Alexander A., et al.
Publicado: (2022)

Cardiac Hepatopathy: New Perspectives on Old Problems through a Prism of Endogenous Metabolic Regulations by Hepatokines
por: Berezin, Alexander A., et al.
Publicado: (2023)

Serum Levels of Irisin Predict Cumulative Clinical Outcomes in Heart Failure Patients With Type 2 Diabetes Mellitus
por: Berezin, Alexander A., et al.
Publicado: (2022)

Discriminative Utility of Apelin-to-NT-Pro-Brain Natriuretic Peptide Ratio for Heart Failure with Preserved Ejection Fraction among Type 2 Diabetes Mellitus Patients
por: Berezin, Alexander A., et al.
Publicado: (2022)

Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus
por: Berezin, Alexander A., et al.
Publicado: (2022)

Emerging Role of Adipocyte Dysfunction in Inducing Heart Failure Among Obese Patients With Prediabetes and Known Diabetes Mellitus
por: Berezin, Alexander E., et al.
Publicado: (2020)

Discriminative Value of Serum Irisin in Prediction of Heart Failure with Different Phenotypes among Patients with Type 2 Diabetes Mellitus
por: Berezin, Alexander A., et al.
Publicado: (2022)

Myokines and Heart Failure: Challenging Role in Adverse Cardiac Remodeling, Myopathy, and Clinical Outcomes
por: Berezin, Alexander E., et al.
Publicado: (2021)

Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification—A Narrative Review
por: Berezin, Alexander E., et al.
Publicado: (2020)

The signature of circulating microparticles in heart failure patients with metabolic syndrome
por: Berezin, Alexander E, et al.
Publicado: (2016)

Editorial: Acute heart failure: From bench to bedside
por: Berezin, Alexander E., et al.
Publicado: (2023)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

Editorial: Prognostication of Heart Failure Evolution: From Circulating Biomarkers to Genetic Risk Predictive Score
por: Berezin, Alexander E., et al.
Publicado: (2021)

Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
por: Yavin, Yshai, et al.
Publicado: (2016)

Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: Relevance to neurohumoral and inflammatory activation
por: Berezin, Alexander E., et al.
Publicado: (2015)

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin
por: Dobner, Stephan, et al.
Publicado: (2022)

The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Sugiyama, Seigo, et al.
Publicado: (2018)

Dapagliflozin Prevents NOX- and SGLT2-Dependent Oxidative Stress in Lens Cells Exposed to Fructose-Induced Diabetes Mellitus
por: Chen, Ying-Ying, et al.
Publicado: (2019)

Correction: Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers
por: Berezin, Alexander E., et al.
Publicado: (2020)

Extracellular Endothelial Cell-Derived Vesicles: Emerging Role in Cardiac and Vascular Remodeling in Heart Failure
por: Berezin, Alexander E., et al.
Publicado: (2020)

Extracellular Vesicles and Thrombogenicity in Atrial Fibrillation
por: Berezin, Alexander E., et al.
Publicado: (2022)

Biomarkers in Heart Failure: From Research to Clinical Practice
por: Berezin, Alexander E., et al.
Publicado: (2023)

Serum Uric Acid Predicts Declining of Circulating Proangiogenic Mononuclear Progenitor Cells in Chronic Heart Failure Patients
por: Berezin, Alexander E., et al.
Publicado: (2014)

Pattern of endothelial progenitor cells and apoptotic endothelial cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fraction
por: Berezin, Alexander E., et al.
Publicado: (2016)

The predictive role of circulating microparticles in patients with chronic heart failure()
por: Berezin, Alexander E., et al.
Publicado: (2014)

The Association of Subclinical Hypothyroidism and Pattern of Circulating Endothelial-Derived Microparticles Among Chronic Heart Failure Patients
por: Berezin, Alexander E., et al.
Publicado: (2015)

The utility of biomarker risk prediction score in patients with chronic heart failure
por: Berezin, Alexander E., et al.
Publicado: (2016)

Data regarding association between serum osteoprotegerin level, numerous of circulating endothelial-derived and mononuclear-derived progenitor cells in patients with metabolic syndrome
por: Berezin, Alexander E., et al.
Publicado: (2016)

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
por: Ott, Christian, et al.
Publicado: (2017)

Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
por: op den Kamp, Yvo J.M., et al.
Publicado: (2022)

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
por: Whaley, Jean M, et al.
Publicado: (2012)

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
por: Karg, M. V., et al.
Publicado: (2018)

SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes
por: Hodrea, Judit, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kadbv7slevj4vsq116p8otkepm